Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Detailed Action
This application is a national stage application of PCT/KR2022/019160, filed November 30, 2022, which claims priority to foreign applications 10-2021-0168330, filed November 30, 2021, and KR10-2021-0168329, filed November 30, 2021. Claims 1-18 are pending in this application. Applicant’s preliminary amendment submitted September 28, 2026, is acknowledged wherein claims 11 and 15 are amended.
Election/Restrictions
Applicant’s provisional election without traverse of group I, claims 1-10, drawn to a composition comprising 1-hydroxyglucitol-D-glucopyranoside, filed September 28, 2026, is acknowledged.
Claims 11-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.
Claims 1-10 are pending in this application and examined on the merits herein.
Claim Objections
Claim 2 is objected to because of the following informalities: The claim refers to the compound (1S)-1-hydroglucitol-D-glucopyranoside, which appears to be the result of a typographical error. The intended f=chemical name appears to be (1S)-1-hydroxyglucitol-D-glucopyranoside Appropriate correction is required.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1 and 3-10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wang et al. (Reference included with PTO-892)
Independent claim 1 is directed to a composition comprising (1S)-1-hydroglucitol-D-glucopyranoside or an isomer thereof. Wang et al. discloses a disaccharide compound fitting this chemical name, (p. 370 figure 4 compound 1) thereby anticipating claim 1. Furthermore the compound is disclosed as a purified product containing no additional components such as monosaccharides, thereby anticipating present claims 1 and 8-10. Regarding claims 4-7, these claims describe intended uses of the compound, but do not contain further structural limitations that would necessarily limit the actual structural composition of the claimed product. Therefore they do not further differentiate the claimed composition from the pure compound described by Wang.
Regarding claim 3, the compound is produced by fermentation of a fungus in a culture medium comprising 20g/L maltose. (p. 367 left column second paragraph) Therefore the unpurified culture medium would anticipate claim 3.
Conclusion
Claims 1 and 3-10 are rejected. Claim 2 is objected to for depending from a rejected base claim but would be allowable if rewritten in independent form incorporating all the limitations of the rejected base claim and any intervening claims.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREA OLSON whose telephone number is (571)272-9051. The examiner can normally be reached M-F 6am-3:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Y Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ANDREA OLSON/ Primary Examiner, Art Unit 1693 10/27/2026